| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 74386 |
cas:146651-71-0，N-Boc-Tris，抗体偶联药物 |
97 |
h |
2024-12-25 |
| 74387 |
BocNH-PEG2-CH2CH2NH2 cas:153086-78-3 |
108 |
zyl |
2024-12-25 |
| 74388 |
Lenvatinib Liposome Lenvatinib，仑伐替尼脂质体 |
119 |
axc |
2024-12-25 |
| 74389 |
Ald-Ph-amido-PEG4-C2-acid，1309460-27-2，抗体- 药物偶联物 |
91 |
hyy |
2024-12-25 |
| 74390 |
mPEG23-OCH2CH2COOH的性质与用途 |
85 |
wyh |
2024-12-25 |
| 74391 |
CBZ-NH-PEG3-CH2CH2COOH cas:1310327-18-4 |
98 |
zyl |
2024-12-25 |
| 74392 |
cas:1821017-46-2，Methyltetrazine-Sulfo-NHS ester |
104 |
h |
2024-12-25 |
| 74393 |
盐酸西替利嗪脂质体，Cetirizine Hydrochloride Liposome |
110 |
axc |
2024-12-25 |
| 74394 |
cas:124529-64-2，tert-butyl 6-(2,5-dioxo-2H-pyrrol-1(5H)-yl)hexylcarbamate |
106 |
h |
2024-12-25 |
| 74395 |
淫羊藿素脂质体(聚乙二醇化)，Icaritin Liposome (PEGylated) |
156 |
axc |
2024-12-25 |
| 74396 |
cas:146474-00-2，1-(2-Aminoethyl)-1H-pyrrole-2,5-dione TFA salt |
114 |
h |
2024-12-25 |
| 74397 |
CBZ-NH-PEG3-CH2COOH cas:462100-05-6 |
120 |
zyl |
2024-12-25 |
| 74398 |
Ald-Ph-amido-PEG2，1061569-06-9，ADC试剂 |
86 |
hyy |
2024-12-25 |
| 74399 |
mPEG24-Hydrazide，甲氧基二十四聚乙二醇酰肼 |
165 |
wyh |
2024-12-25 |
| 74400 |
双氢青蒿素脂质体，Dihydroartemisinin Liposome |
98 |
axc |
2024-12-25 |
| 74401 |
cas:7423-55-4，3-Maleimidopropionic acid，抗体偶联药物 |
192 |
h |
2024-12-25 |
| 74402 |
mPEG11-Hydrazide，甲氧基十一聚乙二醇-酰肼 |
89 |
wyh |
2024-12-25 |
| 74403 |
青蒿素脂质体，Artemisinin Liposome |
152 |
axc |
2024-12-25 |
| 74404 |
cas:2054345-67-2，N3-tris(ethylenoxy)-L-alanine TFA Salt |
99 |
h |
2024-12-25 |
| 74405 |
cas:1155811-37-2 H2N-PEG1-CH2COOtBu的结构式 |
151 |
zyl |
2024-12-25 |
| 74406 |
Ald-Ph-amido-PEG4-C2-NHS ester，1353011-74-1，抗体- 药物偶联物 |
99 |
hyy |
2024-12-25 |
| 74407 |
cas:1398044-54-6，2-t-Butoxycarbonylamino-1,3-bis(carboxyethoxy)propane |
122 |
h |
2024-12-25 |
| 74408 |
2-（2-羟基-5-氨基苯基）苯并咪唑（NH2-HBI） |
116 |
WYQ |
2024-12-25 |
| 74409 |
枸橼酸托法替尼脂质体，Tofacitinib Citrate Liposome |
177 |
axc |
2024-12-25 |
| 74410 |
cas:2028284-70-8，Sulfo DBCO-amine，抗体偶联药物 |
85 |
h |
2024-12-25 |
| 74411 |
四苯基卟啉四磺酸钠（TPPSNa） |
129 |
WYQ |
2024-12-25 |
| 74412 |
DBCO-CONH-PEG12-CH2CH2COONHS的结构式 |
90 |
zyl |
2024-12-25 |
| 74413 |
cas:1353016-70-2，DBCO-acid，抗体偶联药物 |
125 |
h |
2024-12-25 |
| 74414 |
cas:98604-88-7，bis(2,5-dioxopyrrolidin-1-yl) 4,4'-disulfanediyldibutanoate |
159 |
h |
2024-12-25 |
| 74415 |
四-[3-甲氧基-4-(N-咔唑)正丁氧苯基]卟啉（4C4-TPP） |
127 |
WYQ |
2024-12-25 |
| 74416 |
Ald-Ph-amido-PEG3-C1-Boc，1007215-94-2，ADC试剂 |
95 |
hyy |
2024-12-25 |
| 74417 |
mPEG3-Hydrazide，甲氧基三聚乙二醇-酰肼 |
161 |
wyh |
2024-12-25 |
| 74418 |
DBCO-CONH-PEG12-CH2CH2COOH的介绍 |
88 |
zyl |
2024-12-25 |
| 74419 |
cas:1324007-10-4，2,3,4,5,6-pentafluorophenyl 1-[(4-formylphenyl)formamido]-3,6,9,12-tetraoxapentadecan-15-oate |
98 |
h |
2024-12-25 |
| 74420 |
唑来膦酸脂质体，Zoledronic Acid Liposome |
168 |
axc |
2024-12-25 |
| 74421 |
不对称酰胺基卟啉5-(4-棕榈酸酰亚胺基)苯基-10,15,20-三苯基卟啉（PITPPH2） |
120 |
WYQ |
2024-12-25 |
| 74422 |
盐酸拓扑替康脂质体(聚乙二醇化)，Topotecan Hydrochloride Liposome (PEGylated) |
148 |
axc |
2024-12-25 |
| 74423 |
DBCO-CONH-PEG4-CH2CH2COONHS的结构式 |
112 |
zyl |
2024-12-25 |
| 74424 |
perfluorophenyl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13-tetraoxa-4-azahexadecan-16-oate |
94 |
h |
2024-12-25 |
| 74425 |
他莫昔芬脂质体，Tamoxifen Liposome |
113 |
axc |
2024-12-25 |
| 74426 |
2,5-dioxopyrrolidin-1-yl 1-(cyclooct-2-ynyloxy)-2-oxo-6,9,12,15-tetraoxa-3-azaoctadecan-18-oate |
117 |
h |
2024-12-25 |
| 74427 |
Methyltetrazine-CH2NHCO-PEG9-Biotin |
97 |
zyl |
2024-12-25 |
| 74428 |
藤黄酸脂质体，Gambogic Acid Liposome |
91 |
axc |
2024-12-25 |
| 74429 |
cas:1006592-59-1，2,5-dioxopyrrolidin-1-yl 3-(2-(2-undec-10-ynamidoethoxy)ethoxy)propanoate |
97 |
h |
2024-12-25 |
| 74430 |
Ald-Ph-amido-PEG3-C2-Pfp ester，2101206-21-5，抗体- 药物偶联物 |
93 |
hyy |
2024-12-25 |
齐岳微信公众号
官方微信
库存查询